瑞舒伐他汀联合曲美他嗪治疗老年ICM心衰的疗效

目的 观察瑞舒伐他汀联合曲美他嗪治疗老年缺血性心肌病（ICM）心力衰竭的短期疗效.方法 选择老年ICM心力衰竭患者92例,随机分为对照组和观察组,各46例.所有患者均接受利尿剂、β受体阻滞剂、血管紧张素转换酶抑制剂（ACEI）/血管紧张素Ⅱ受体拮抗剂（ARB）、抗凝制剂、抗血小板制剂、洋地黄类、硝酸酯类药物等的常规抗心衰治疗,对照组在此基础上加用曲美他嗪20 mg（3次/d,口服）,观察组在此基础上联用瑞舒伐他汀10 mg（1次/d,口服）和曲美他嗪20 mg（3次/d,口服）.疗程均为6个月.观察两组治疗前后临床疗效及左室收缩末内径（LVESD）、左室舒张末内径（LVEDD）、左室射血分数（LVEF）及6 min步行距离测试（6MWT）.结果 观察组的LVESD、LVEDD、LVEF、6MWT均明显优于对照组（P＜0.05）;观察组整体疗效明显优于对照组（P＜0.05）;两组均无肝肾功能异常.结论 瑞舒伐他汀联合曲美他嗪治疗老年ICM心力衰竭短期疗效显著,且无明显不良反应.

Curative effects of rosuvastatin combined with trimetazidine on senile patients with ischemic cardiomyopathy heart failure

Objective To observe the short-tetra curative effects of rosuvastatin combined with trimetazidine on senile patients with ischemic cardiomyopathy （ ICM ） heart failure. Methods 92 senile patients with ICM heart failure were selected and randomly divided into control and observation groups with 46 ones in each group. All patients received conventional anti-heart failure therapy with diuretic, p-receptor blocking, ACEVARB, anticoagulant, antiplatelet agent, digitaloid drugs, and nitric acid ester, etc. Based on the treatment above, the control group orally took additional 20 mg trimetazidine （ tid）, and the observation group orally took additional 20 mg trimetazidine（tid）eombined with 10 mg rosuvastatin（qd）. The course of treatment was 6 months. Observation was made in the clinical curative effects, left ventricular end systolic diameter （ LVESD ）, left. ventricular end diastolic diameter （ LVEDD）, left ventficular ejection fraction（LVEF） , and 6-minute walk test（6MWT）before and after treatment. Results The levels of LVESD, LVEDD, LVEF, and 6MWT in the observation group were all significantly better than those in the control group（ P 〈 0.05 ）. The overall curative effect of the observation group was significantly superior to that of the control group （ P 〈 0.05 ）. No disorder of liver and kidney function appeared in both groups. Conclusion Rosuvastatin combined with trimetazidine has better short-term curative effect on senile patients with ICM heart failure and no obvious adverse reaction.